Diabetic kidney disease (DKD) is caused by microvascular damage sustained as a result of diabetes and is the leading cause of chronic kidney disease (CKD) . CKD affects 12% of people and will be the fifth cause of mortality worldwide in 2040 . In 2021, an estimated 537 million people were estimated living with diabetes, 40% of whom are expected to develop DKD . The main early marker of this disease is albuminuria (i.e., presence of albumin in the urine), which identifies the risk of progression of DKD and it is a therapeutic target and surrogate marker of clinical events . Given the predictive value of albuminuria for the outcome of the disease , there is a need for an affordable and portable screening tool that can detect albumin, unlike immunoassay-based autoanalyzers, which provide optimal analytical and clinical performance but are best suited for batch analysis in hospital clinical laboratories. Urine dipsticks are the main screening tool, but have low sensitivity and specificity in the microalbuminuria range (30-300 mg/L) . Considering the severity and high prevalence of DKD, the importance of accurately detecting and monitoring albuminuria should be accessible at any point of care within the health system such as pharmacies and primary care units.